Medison Issues Presentation to Knight Shareholders

About this update from Knight Therapeutics, Inc.

[{"type":"text","content":"\n\n\n\nMedison Issues Presentation to Knight Shareholders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nPETACH TIKVA, Israel, April 18, 2019\n\n\n\nMakes Case for Urgent Change, Improved Governance and a Common-Sense Strategic Growth Plan Details History of Failed Execution, Underperformance and Conflicts of Interest Under Current Board and CEO Provides Background on Experienced, Independent Director Nominees That Can Effect Positive Change Rebuts Knight's Campaign of Misinformation and Harassment Against Shareholders PETACH TIKVA, Israel, April 18, 2019 /CNW/ - Medison Biotech (1995) Ltd. (\"Medison\"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (\"Knight\" or the \"Company\"), today made its case for urgent change, improved governance and a promising future at the Company in a detailed presentation to shareholders.  The full presentation can be downloaded at www.NewDayForKnight.com.\nMeir Jakobsohn, CEO of Medison, said, \"Knight has failed and the need for change is indisputable.  Hobbled by a conflicted Board of Directors and CEO who have no strategy, the Company has failed to realize its vision and deliver value for shareholders.  Knight's underperforming stock price, which attributes insignificant value to Knight's pharmaceutical business, is a clear reflection of shareholders' disappointment with Knight's progress.\"\nMedison's presentation to shareholders details why change is urgently needed at Knight in order to build a sustainable pharma business and long-term value for its shareholders.  These reasons include:\nIn five years as a public company, Knight has failed to build successful pharmaceutical operations.Knight's stock, buoyed only by its $787 million in cash on the balance sheet, has been flat for more than three years while market indexes and pharma stocks have appreciated substantially.The market recognizes Knight's lack of operating business and prospects by currently valuing the Company as if i...

More updates from Knight Therapeutics, Inc.